BG65618B1 - Use of anti-snake venom serum for cerebral insult treatment - Google Patents

Abstract

The means is administered for the treatment of cerebral insult in an ititial stage, both in clinically and in outpatient treatment. By it. quick and efficient effect on the morbid process is attained, requiring no precision establishment of the diagnosis of its kind, and it can, furrthermore, be administered parallel to known means and methods. The means is antivenomous snake serum produced from warm-blooded animal, pretreated with venomous snake poison.

Description

Technical field

The invention relates to the use of a product of animal origin, in particular anti-isthmia serum, for the manufacture of medicaments for use in human medicine for the treatment of stroke in the initial stage, both in the clinical and in the home setting.

BACKGROUND OF THE INVENTION

Immediate therapeutic effects in improving brain blood flow, responding to rapid brain edema and efforts to prevent pulmonary, cardiac and other complications are essential in the outcome of cerebral infarctions.

Improvement of cerebral blood flow is accomplished by influencing the hemorheological parameters. To this end, hypovolemic or iso-hypovolemic low-molecular-weight dextran hemodilution (Hemodex, Reoisodex) is used. A good effect is also obtained by infusing low molecular weight dextran [1].

In addition to hemodilution, pentoxifylline and acetyl are administered. The inclusion of high doses of antistenocardin is also appropriate [1].

Anticoagulant treatment is recommended for subacute progressive cerebral infarction, when the paretic phenomena increase gradually but no hemiplegia has developed. Red heart attack is a counter indication for anticoagulation. It is contraindicated in hypertension. The treatment is performed with heparin, coumarone and indandione preparations [2].

To improve the brain blood flow, if the patient is not in a serious condition and the general circulation is stabilized, vasodilators (Cavinton, Duzodrill, Nimodipine, Halidor, etc.) are also used. Their appointment is not desirable in severe brain swelling with delusional consciousness. , because of the risk of blood redistribution and its abduction to areas unaffected by cerebral infarction [3].

In cerebral infarctions, the response to fast-growing cerebral edema is affected. Mannitol, glycerol, corticosteroids and less frequently diuretics are used.

In the treatment of the brain also apply agents that directly affect brain metabolism. To this end, pyramem (nootropil) is used in venose + a drip infusion [4].

The treatment of cerebral infarctions involves the prevention of lung and other complications and the timely removal of water-electrolyte and alkaline disorders.

Drug treatment for hemorrhage includes agents for controlling arterial hypertension and for tracranial pressure.

Hyperosmolar solutions of mannitol, sorbitol or glycerol steroids, spironolactone and barbiturates are used to lower intracranial pressure [5]. The counter-effect of cortium / steroids is still under discussion. They are usually combined with diuretics. Recently, large doses of barbiturates have been used to lower intracranial pressure.

[6] a composition known to be toxic toxin from snake venom derived from Bungari snakes from Bung1; and the genus True cobra (Naja), πρι treatment of progressive degenerative neurological diseases, such as amyotrins] of sclerosis, multiple sclerosis, poliomyositis, meningitis, muscular dystrophy and others. similar.

From [7], a composition known to be toxic neurotoxin from the venom of the snake of the genus Genuine Cobra (Naja) is known for the treatment of: diseases like amyotro!

of sclerosis, multiple sclerosis, poliomyositis, meningitis, muscular dystrophy and more.

From [8] known is a composition, an effective amount of a psychnaptic neurotoxin derived from the poison Naja, the genus Ophiophagus or the genus Mambi (Dendroaspis), a presynaptic neurotoxin derived from a Bungarus poison and a stimulant component mechanisms of the body, include the necessary infarction

-acid is the brain's desire for an inrol, corticosterone (Bungarus) or Ari (Bungarus) designated as pichalateral, containing a neurologic lateral effect which contains snakes of the genus Snake

65618 Bleeding snake venom from the Vivera family, subfamily Snake Crotalinae. The composition is intended for the treatment of neurological diseases.

In the literature and medical practice, there is no known composition or agent for the treatment of stroke, in particular, especially effective in the early stages of the disease process obtained from an animal source.

SUMMARY OF THE INVENTION

The agent according to the invention is an anti-serpent serum, which is obtained from the serum of a warm-blooded animal after application of a snake venom by injection of progressively increasing doses, for example poison from Vipera ammodytes. Horses are most commonly used for production because serum production is also highest. The preparation of rabbit or other small mammal serum is made in limited quantities in order to be administered to patients who have developed an allergy to horse-derived serum.

It is recommended that the agent according to the invention be administered as follows: after diagnosis the stroke (infarction or hemorrhage) of the patient is premedicated with an antihistamine preparation and after 100-30 minutes administered 100 E anti-isthmia serum dissolved in bank saline or Serum glukosae in a slow drop. A total of 100 E of anti-isthmus serum with premedication at 12-hour intervals may be administered within 24 hours. Treatment should be continued for three to five days, in combination with previously known stroke management. When allergy develops, it can be replaced with anti-isthmus serum derived from rabbit or other small mammal.

The advantages of the agent according to the invention are: fast and efficient response to the disease process and the patient's condition, convenience of application - it is not necessary to apply it in a hospital setting and does not require special medical equipment, versatility of the preparation - does not require the precision of the type diagnosis (hemorrhage or thrombosis) can be applied in parallel with known means and methods. The anti-serpent sera are known to have pharmacopoeial requirements, which are authorized for production and use on the market, available in 100E.

Examples of embodiments of the invention are the injection of animals, testing the effect of P1 anti-serpent serum on experimental animals. Wistar rats weighing 250 to 300 g, anesthetized with nembutal 35 mg / kg intraperitoneally, were used for the experiments. 4 groups of animals were studied - control, with cerebral hemorrhage, with cerebral hemorrhage, and with anti-isthmia serum treatment and with a group of experimental snake bites.

The cerebral haemorrhage was ι blood clothed as 2 mm in the right parietal lcb at a depth of 5 mm for a period of 5 min slowly 100 microl autologous blood. The ito will be treated with anti-isthmia serum was previously cannulated ia the right artery jugular. In the 10th minute after the provocation of the hemorrhage, it was injected; ha of 100 microl antiallerzine (ampoule of 2 cc 0.05) and in the 15th minute after hemorrhage - 401, anti-isthmus serum (1 ampoule has 100 E). The experimental snake bite produced 1.25 mg of Vipera ammodytes poison with 1 ml saline for 150 g injected 0.5 intramuscularly into the two gluteal regions of the rats. Blood προί and were taken as follows: control group and group (10 rats each) at 3 in the 60th minute, 8th hour, 16-1 hour. After blood sampling, the rats were excised and the lungs and brain were fixed in 10% formalin and examined pathomorphologically. The biochemical parameters studied showed statistically significant deviation in rats with cerebral hemorrhage and snake bite as early as the 30th minute. There is a great similarity in the pathobiochemistry of the two diseases. Pathomorphology reveals the development of shock lung at hemorrhage and snake bite as early as the 8th hour, as well as the development of cerebral edema. In the group of anti-isthmus-treated serum, the indices remained close to controls and were not recaptured by extending each other at the 0th minute, hour and 24th.

65618 Bl human abnormalities in pathomorphology.

The use of anti-snake serum will be more beneficial if treatment is given within the first minutes or hours after the onset of the incident.

Claims (1)

Claims Use of an anti-serpent serum derived from a warm-blooded animal, previously treated with snake venom, for the manufacture of a medicament for the treatment of stroke, in particular in the early stages of the disease process.